DHR Danaher Corporation - Fundamental Analysis
NEUTRAL
DHR Stock | Fundamental Analysis & Investment Insights
NYSE
•
Healthcare
•
Diagnostics & Research
Current Price
$221.21
Analyst Target
$254.2
+14.9% Upside
52W High
$258.23
52W Low
$171.0
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
65%
Analysis Accuracy
Danaher Corporation trades at a significant premium to both the healthcare sector and its closest peers, with a P/E of 45.42 versus a sector average of 26.61 and peer TMO at 33.45, raising valuation concerns despite solid underlying profitability and a conservative capital structure. The company exhibits strong gross margins (59.59%) and operating leverage (20.75% operating margin), but recent insider selling—over $235M in the last six months—signals caution at current levels. While earnings growth (13.4% YoY) and recent price momentum (6M +13.2%, 1M +7.3%) are positive, the lack of earnings surprise visibility and weak long-term price performance (1Y -7.0%, 3Y -6.3%) constrain near-term upside. Analysts project a 15% upside to $254.20, but with no clear consensus recommendation and missing ROIC/cash flow data, confidence in the fair value is tempered.
Key Strengths
Exceptional gross margin of 59.59%, reflecting pricing power and operational efficiency in Diagnostics & Research
Operating margin of 20.75% well above sector average of ~15%, indicating strong cost discipline
Low debt/equity ratio of 0.36, providing significant financial flexibility relative to peers like AMGN (5.67)
Forward P/E of 26.40 suggests de-rating potential if growth materializes, closer to TMO's 33.45
Recent positive price momentum: +13.2% over 6M and +7.3% over 1M, signaling technical strength
Key Risks
Current P/E of 45.42 is 70% above sector average (26.61), creating vulnerability to multiple contraction
Insider selling of $235.12M in 6 months, including large blocks by officers and directors, implies lack of confidence at current valuation
Missing quarterly earnings data prevents assessment of earnings quality and consistency over 25 quarters
ROE of 6.84% is weak versus sector average of 25.21% and peer AMGN at 81.71%, suggesting poor capital allocation efficiency
Revenue growth of 4.4% lags sector average of 10.85%, limiting top-line expansion narrative
AI Fair Value Estimate
Based on comprehensive analysis
$254.2
+14.9% above current price
Performance Snowflake
Multi-dimensional AI analysis across 5 key categories
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Historical Performance Trends
Long-term financial metrics and growth patterns
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability, Growth & Financial Health
Detailed profit margins, ROE, debt ratios, and liquidity metrics
Sector Comparison & Peer Analysis
Compare DHR against industry averages and similar companies
Insider Trading & Analyst Ratings
Track insider transactions and Wall Street analyst recommendations